Danial Nadeem, Mahdi Taye, Matthew D Still, Shannon McShea, Daniel Satterfield, James T Dove, G Craig Wood, Benyam D Addissie, David L Diehl, Amitpal S Johal, Harshit S Khara, Bradley D Confer, Christopher D Still
BACKGROUND AND AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) promote weight loss by suppressing appetite, enhancing satiety, regulating glucose metabolism and delaying gastric motility. We sought to determine whether GLP-1 RA use could impact sedated medical procedures like esophagogastroduodenoscopy (EGD). METHODS: We conducted a retrospective study on 35,183 patients who underwent EGD between 2019 and 2023, 922 of which were using a GLP-1-RA. Data were collected regarding demographics, diabetes status, retained gastric contents during EGD (RGC), incidence of aborted EGD, and necessity for repeat EGD...
April 29, 2024: Gastrointestinal Endoscopy